Adenosine Deaminase-Severe Combined Immunodeficiency Market Report 2026

The adenosine deaminase-severe combined immunodeficiency market size has grown strongly in recent years. It will grow from $5.94 billion in 2025 to $6.33 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to limited awareness of ada-scid, low availability of gene therapy solutions, reliance on supportive care treatments, lack of specialized treatment centers, high prevalence of treatment delays.

The adenosine deaminase-severe combined immunodeficiency market size is expected to see strong growth in the next few years. It will grow to $8.11 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to advancements in autologous stem cell therapies, increasing enzyme replacement therapy accessibility, growth in specialized hospitals and clinics, rising pediatric diagnosis rates, increasing healthcare funding for rare genetic disorders. Major trends in the forecast period include increasing adoption of enzyme replacement therapies, rising development and access to gene therapy solutions, growth in stem cell transplantation procedures, expansion of pediatric treatment programs for ada-scid, enhanced focus on supportive care and patient monitoring.

The rising prevalence of genetic disorders is expected to drive the growth of the adenosine deaminase-severe combined immunodeficiency market going forward. Genetic disorders are medical conditions that arise from abnormalities or mutations in an individual’s DNA, which may be inherited or occur spontaneously. The increasing occurrence of genetic disorders is influenced by factors such as advancements in diagnostic technologies, greater awareness, higher parental age, environmental factors, and population growth. The growing prevalence of genetic disorders, particularly rare conditions such as adenosine deaminase-severe combined immunodeficiency (ADA-SCID), is increasing the demand for advanced diagnostic approaches and targeted therapeutic solutions. For instance, in October 2024, according to the Cystic Fibrosis Trust, a UK-based national charity, 11,148 individuals were living with cystic fibrosis in the UK in 2022, which rose to 11,318 in 2023. Therefore, the rising prevalence of genetic disorders is driving the growth of the adenosine deaminase-severe combined immunodeficiency market.

Major organizations operating in the adenosine deaminase-severe combined immunodeficiency treatment market are concentrating on developing advanced approaches, such as in-house gene therapy production, to improve patient accessibility, lower treatment costs, and maintain supply reliability. In-house gene therapy production involves manufacturing autologous hematopoietic stem cells genetically modified with a functional ADA gene within an organization’s own facilities, reducing reliance on external manufacturers. For instance, in February 2025, Fondazione Telethon, an Italy-based nonprofit biomedical research organization, submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for etuvetidigene autotemcel, a gene therapy initially developed for ADA-SCID and later expanded to target Wiskott-Aldrich Syndrome. This therapy involves a single administration of autologous CD34+ stem and progenitor cells transduced with a lentiviral vector carrying the functional gene and has demonstrated encouraging safety and efficacy results in treated patients.

In January 2024, Kyowa Kirin Co., Ltd., a Japan-based pharmaceutical company, acquired Orchard Therapeutics plc. for an undisclosed amount. This acquisition was intended to reinforce Kyowa Kirin’s focus on delivering innovative treatments for rare and complex diseases by utilizing Orchard Therapeutics’ gene therapy platform. Orchard Therapeutics plc is a UK-based gene therapy company specializing in the development of gene therapies for rare genetic disorders.

Major companies operating in the adenosine deaminase-severe combined immunodeficiency market are GlaxoSmithKline plc, Chiesi Farmaceutici S.p.A., Orchard Therapeutics PLC, Rocket Pharmaceuticals, Novartis AG, Bluebird Bio, Spark Therapeutics, Leadiant Biosciences, Sigma-Tau Pharmaceuticals, Astellas Pharma, Takeda Pharmaceutical Company, Pfizer Inc, Sanofi, Bristol-Myers Squibb, Roche Holding AG, Johnson & Johnson, AbbVie Inc, Gilead Sciences, CSL Limited, Bayer AG.

North America was the largest region in the adenosine deaminase-severe combined immunodeficiency market in 2025. The regions covered in the adenosine deaminase-severe combined immunodeficiency market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adenosine deaminase-severe combined immunodeficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the adenosine deaminase-severe combined immunodeficiency market by increasing costs for imported enzyme replacement therapies, gene therapy reagents, and stem cell transplantation equipment. Segments such as enzyme replacement therapy and gene therapy are most affected, with north america, europe, and asia-pacific regions facing higher import duties. This has led to elevated treatment costs and delayed access in certain regions. On the positive side, tariffs have incentivized local production and regional development of rare disease therapies, fostering innovation and self-reliance.

The adenosine deaminase-severe combined immunodeficiency market research report is one of a series of new reports that provides adenosine deaminase-severe combined immunodeficiency market statistics, including adenosine deaminase-severe combined immunodeficiency industry global market size, regional shares, competitors with a adenosine deaminase-severe combined immunodeficiency market share, detailed adenosine deaminase-severe combined immunodeficiency market segments, market trends and opportunities, and any further data you may need to thrive in the adenosine deaminase-severe combined immunodeficiency industry. This adenosine deaminase-severe combined immunodeficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Adenosine deaminase-severe combined immunodeficiency (ADA-SCID) is a rare genetic disorder caused by a deficiency of the enzyme adenosine deaminase, resulting in the toxic buildup of metabolites that disrupt immune cell development. Understanding ADA-SCID is important for early diagnosis and management of the condition, helping to prevent life-threatening infections and related complications.

The main treatment options for adenosine deaminase-severe combined immunodeficiency include enzyme replacement therapy, gene therapy, stem cell transplantation, and supportive care. Enzyme replacement therapy (ERT) involves the administration of synthetic or recombinant enzymes to compensate for a deficient or missing enzyme in individuals with specific genetic disorders. These therapies are delivered through various routes, including intravenous, subcutaneous, and oral, and are intended for both pediatric and adult patients. They are distributed through hospital, retail, and online pharmacies, with key end users including hospitals, specialty clinics, research institutes, and others.

The adenosine deaminase-severe combined immunodeficiency market consists of revenues earned by entities by providing services such as diagnosis and genetic testing, therapy services, and consultation & genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The adenosine deaminase-severe combined immunodeficiency market also includes sales of diagnostic tools, supportive therapies, and genetic testing kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.